Pegmusirudin

Drug Profile

Pegmusirudin

Alternative Names: LU 57291; PEG-hirudin - Speedel; SPP-200

Latest Information Update: 29 Jan 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott GmbH & Co. KG
  • Class Antithrombotics; Hirudins
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Blood coagulation disorders; Coronary disorders; Unstable angina pectoris; Vascular graft occlusion

Most Recent Events

  • 22 Dec 2009 No development reported - Phase-II for Vascular graft occlusion in USA (Parenteral)
  • 29 Aug 2006 Speedel has retained all development, commercialisation and marketing rights to pegmusirudin from Abbott Laboratories
  • 13 Mar 2001 BASF's pharmaceutical business has been acquired by Abbott Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top